Humira
Autoimmune disorders
Key Facts
About Royalty Pharma
Founded in 1996, Royalty Pharma pioneered the royalty pharma asset class by providing non-dilutive capital to pharmaceutical innovators. The company has deployed over $19 billion to acquire royalty interests in leading medicines across multiple therapeutic areas. As a publicly-traded company on NASDAQ, Royalty Pharma generates revenue from royalty payments on successful drugs while helping fund the next generation of medical breakthroughs.
View full company profileAbout Abbott India
Abbott India operates as a publicly traded subsidiary of Abbott Laboratories, focusing on bringing innovative healthcare solutions to the Indian market. The company has established a strong presence across multiple therapeutic areas including cardiology, diabetes care, women's health, and nutrition. With manufacturing facilities and a robust distribution network across India, Abbott India plays a crucial role in making quality healthcare accessible to diverse patient populations throughout the subcontinent.
View full company profileTherapeutic Areas
Other Autoimmune disorders Drugs
| Drug | Company | Phase |
|---|---|---|
| Immunomodulation Programs | Fosun Pharma | Various Phases |
| Adalimumab Biosimilar | Glenmark Pharmaceuticals | Phase 3 |
| Autoimmune Disease Programs | TScan Therapeutics | Discovery |
| Autoimmune Diagnostics (Immco) | Trinity Biotech | Approved/Commercial |
| TYK2 Pseudokinase Inhibitor | A2A Pharma | Preclinical |